Skip to main content

Select Drug Profiles

Original Research, Cardiometabolic Health
Can Academic Detailing Move the Needle for Patients with Diabetes in a State-Based Prescription Drug Benefit Program?
Dominick P. Trombetta, PharmD, BCPS, BCGP, Debra A. Heller, PhD, MPH
Dominick P. Trombetta, PharmD, BCPS, BCGP; Debra A. Heller, PhD, MPH
Read More
Perspectives
Pharmacy Integration
David B. Nash, MD, MBA
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
The Economic Value of Customized versus Off-the-Shelf Knee Implants in Medicare Fee-for-Service Beneficiaries
Mary I. O’Connor, MD, Brittany E. Blau, MPH
Mary I. O’Connor, MD; Brittany E. Blau, MPH
Read More
FDA Approvals
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, In the News
April 16, 2019 – FDA Approvals, News & Updates
Read More
FDA Approvals
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala
Read More
FDA Approvals
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Loretta Fala
Read More
FDA Approvals
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh
Read More
Page 54 of 244
Results 531 - 540 of 2434